Bleomycin in testicular cancer: Will pharmacogenomics improve treatment regimens?

Journal of Clinical Oncology

Volumn 26, Issue 11, 2008, Pages 1783-1785

  Bokemeyer, Carsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BLEOMYCIN HYDROLASE; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; ENZYME INACTIVATION; GENOTYPE; GERM CELL TUMOR; HEAD AND NECK CANCER; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KAPOSI SARCOMA; LUNG FIBROSIS; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PHARMACOGENOMICS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TESTIS CANCER; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; GENETIC POLYMORPHISM; GENETICS; MALE; NEOPLASM; NOTE; PHARMACOGENETICS; PROGNOSIS; TESTIS TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; ETOPOSIDE; GENOTYPE; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROGNOSIS; PULMONARY FIBROSIS; TESTICULAR NEOPLASMS;

EID: 42949118857     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.2991     Document Type: Editorial

References (13)

1. Azambuja E, Fleck JF, Batista RG, et al: Bleomycin lung toxicity: Who are the patients with increased risk? Pulm Pharmacol Ther 18:363-366, 2005
2. Lazo JS, Boland CJ, Schwartz PE: Belomycin hydrolase activity and cytotoxicity in human tumors. Cancer Res 42:4026-4031, 1982
3. Chen XL, Li WB, Zhou AM, et al: Role of endogenous peroxynitrite in pulmonary injury and fibrosis induced by bleomycin A5 in rats. Acta Pharmacol Sin 24:697-702, 2003
4. de Wit R: Refining the optimal chemotherapy regimen in good prognosis germ cell cancer: Interpretation of the current body of knowledge. J Clin Oncol 25:4346-4349, 2007
5. O'Sullivan JM, Huddart RA, Norman AR, et al: Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14:91-96, 2003
6. de Haas EC, Zwart N, Meijer C, et al: GVariation in Bleomycin Hydrolase Gene is Associated with Reduced Survival after Chemotherapy for Testicular Germ Cell Cancer. J Clin Oncol 26:1817-1823, 2008
7. Van Kuilenburg AB, Meinsma R, Zoetekouw L, et al: High prevalence of the IVS14+ 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patietns with severe 5-fluorouracil-associated toxicity. Phamacogenetics 12:555-558, 2002
8. Lazo JS, Humphreys CJ: Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity. Proc Natl Acad Sci U S A 80:3064-3068, 1983
9. Brömme D, Rossi AB, Smeekens SP, et al: Human bleomycin hydrolase: Molecular cloning, sequencing, functional expression, and enzymatic characterization. Biochem 35:6706-6714, 1996
10. Nuver J, Lutke Holzik MF, van Zweeden M, et al: Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. Pharmacogenet Genom 15:399-405, 2005
11. de Wit R, Stoter G, Kaye SB, et al: Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15:1837-1843, 1997
12. de Wit R, Roberts JT, Wilkinson PM, et al: Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19:1629-1640, 2001
13. Culine S, Kerbrat P, Kramar A, et al: Refining the optimal chemotherapy regimen for good-risk metastatic nonsemimatous germ-cell tumors: A randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUC T93BP). Ann Oncol 18:917-924, 2007